Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialJörge E. Cortes, Mark J. Levis, Philippe Rousselot et al.|The Lancet Oncology|2018Cited by 268
Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell TransplantationMark J. Levis, Jörge E. Cortes, Alexander E. Perl et al.|Blood|2012Cited by 141
Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid LeukemiaJörge E. Cortes, Mark J. Levis, Alexander E. Perl et al.|Blood|2012Cited by 121